87 related articles for article (PubMed ID: 25796944)
1. [Erythrocyte aggregation in patients with arterial hypertension and dyslipidemia treated with pravastatin].
Medvedev IN; Skoriatina IA
Klin Med (Mosk); 2014; 92(11):34-8. PubMed ID: 25796944
[TBL] [Abstract][Full Text] [Related]
2. Effects of simvastatin and pravastatin on peroxidation of erythrocyte plasma membrane lipids in patients with type 2 hypercholesterolemia.
Koter M; Franiak I; Broncel M; Chojnowska-Jezierska J
Can J Physiol Pharmacol; 2003 May; 81(5):485-92. PubMed ID: 12774855
[TBL] [Abstract][Full Text] [Related]
3. [Dynamics of microrheologic properties of erythrocytes in patients with arterial hypertension and dyslipidemia treated with atorvastatin].
Medvedev IN; Skoriatina IA
Klin Med (Mosk); 2012; 90(6):42-5. PubMed ID: 22997720
[TBL] [Abstract][Full Text] [Related]
4. [Effect of atorvastatin on hemorheological parameters in patients with arterial hypertension with dyslipidemia].
Abrashkina ED; Shaalali N; Pakhrova OA; Shutemova EA; Nazarova OA
Kardiologiia; 2010; 50(5):25-8. PubMed ID: 20831044
[TBL] [Abstract][Full Text] [Related]
5. [The comparison in vitro the effects of pravastatin and quercetin on the selected structural parameters of membrane erythrocytes from patients with hypercholesterolemia].
Broncel M; Franiak I; Koter-Michalak M; Duchnowicz P; Chojnowska-Jezierska J
Pol Merkur Lekarski; 2007 Feb; 22(128):112-6. PubMed ID: 17598654
[TBL] [Abstract][Full Text] [Related]
6. Risk reductions for cardiovascular disease with pravastatin treatment by dyslipidemia phenotype: a post hoc analysis of the MEGA Study.
Nishiwaki M; Ikewaki K; Ayaori M; Mizuno K; Ohashi Y; Ohsuzu F; Ishikawa T; Nakamura H;
J Cardiol; 2013 Mar; 61(3):196-200. PubMed ID: 23265677
[TBL] [Abstract][Full Text] [Related]
7. The effect of atorvastatin on erythrocyte membranes and serum lipids in patients with type-2 hypercholesterolemia.
Koter M; Broncel M; Chojnowska-Jezierska J; Klikczynska K; Franiak I
Eur J Clin Pharmacol; 2002 Nov; 58(8):501-6. PubMed ID: 12451426
[TBL] [Abstract][Full Text] [Related]
8. [The aggregation capacity of neutrophils in patients with arterial hypertension and dyslipidemia treated with fluvastatin].
Medvedev IN; Skoryatina IA
Klin Med (Mosk); 2015; 93(1):66-70. PubMed ID: 26031153
[TBL] [Abstract][Full Text] [Related]
9. [Effect of lovastatin on adhesive and aggregation function of platelets in patients with arterial hypertension and dislipidemia].
Medvedev IN; Skoriatina IA
Klin Med (Mosk); 2010; 88(2):38-40. PubMed ID: 21105469
[TBL] [Abstract][Full Text] [Related]
10. Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study.
Ballantyne CM; Miller M; Niesor EJ; Burgess T; Kallend D; Stein EA
Am Heart J; 2012 Mar; 163(3):515-21, 521.e1-3. PubMed ID: 22424025
[TBL] [Abstract][Full Text] [Related]
11. The effectiveness and safety of low dose pravastatin in elderly hypertensive hypercholesterolemic subjects on antihypertensive therapy.
Chan P; Lee CB; Lin TS; Ko JT; Pan WH; Lee YS
Am J Hypertens; 1995 Nov; 8(11):1099-104. PubMed ID: 8554733
[TBL] [Abstract][Full Text] [Related]
12. [The effect of aspirin on rheological properties of erythrocytes in essential hypertension].
Korbut RA; Adamek-Guzik T
Przegl Lek; 2002; 59(2):71-5. PubMed ID: 12152252
[TBL] [Abstract][Full Text] [Related]
13. Influence of cholesterol-lowering on plasma membrane lipids and function.
Lijnen P; Echevaría-Vázquez D; Petrov V
Methods Find Exp Clin Pharmacol; 1996 Mar; 18(2):123-36. PubMed ID: 8740244
[TBL] [Abstract][Full Text] [Related]
14. A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial.
Preston RA; Harvey P; Herfert O; Dykstra G; Jukema JW; Sun F; Gillen D
J Clin Pharmacol; 2007 Dec; 47(12):1555-69. PubMed ID: 18048574
[TBL] [Abstract][Full Text] [Related]
15. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
Saklamaz A; Comlekci A; Temiz A; Caliskan S; Ceylan C; Alacacioglu A; Yesil S
Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effect of lipophilic and hydrophilic statins on serum adiponectin levels in patients with mild hypertension and dyslipidemia: Kinki Adiponectin Interventional (KAI) Study.
Kai T; Arima S; Taniyama Y; Nakabou M; Kanamasa K
Clin Exp Hypertens; 2008 Oct; 30(7):530-40. PubMed ID: 18855257
[TBL] [Abstract][Full Text] [Related]
17. [Clinical efficacy of combined therapy with enalapril + trimetazidine in patients with hypertension comorbid with ischemic heart disease and metabolic disturbances].
Petelina TI; Gapon LI; Bakhmatova IuA; Zhevagina IA
Ter Arkh; 2005; 77(8):19-23. PubMed ID: 16206600
[TBL] [Abstract][Full Text] [Related]
18. [Treatment for dyslipidemias in patients with arterial hypertension].
Chazova IE; Kukharchuk VV; Ratova LG; Kaminnaia VI
Ter Arkh; 2007; 79(4):53-7. PubMed ID: 17564020
[TBL] [Abstract][Full Text] [Related]
19. [FEATURES MANIFESTATIONS COMORBID CURRENTS OF GASTROESOPHAGEAL REFLUX DISEASE AND ARTERIAL HYPERTENSION DEPENDING ON THE DEGREE OF ARTERIAL HYPERTENSION].
Fadieienko G; Gridniev O
Georgian Med News; 2015 Nov; (248):21-9. PubMed ID: 26656546
[TBL] [Abstract][Full Text] [Related]
20. Changes of lipid peroxides and antioxidative factors levels in blood of patients treated with ACE inhibitors.
Djordjević VB; Pavlović D; Pejović M; Cvetković T; Lecić N; Deljanin-Ilić M
Clin Nephrol; 1997 Apr; 47(4):243-7. PubMed ID: 9128791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
